Gryphon Scientific has recently been acquired by Deloitte to expand its biosafety, biosecurity, public health, and emergency preparedness and response capabilities. As part of the acquisition, Deloitte will integrate Gryphon’s team of scientists, programmers, data analysts, public health specialists, and planning and policy professionals with expertise in scientific communications, modeling, data science, and risk assessment.
The collaboration between the two companies will focus on developing artificial intelligence applications through Deloitte’s Federal Health AI Accelerator. These applications will aim to enhance public health and safety measures and assist clients in preparing for chemical threats, biothreats, and other biological emergencies.
Beth Meagher, who serves as the U.S. federal health sector leader and principal at Deloitte Consulting, expressed enthusiasm about the addition of Gryphon’s professionals and leadership to the consulting firm. She emphasized that this move enhances Deloitte’s data analytics and advanced tech capabilities and will enable them to support federal agencies in safeguarding national security and public health.
Meagher added that their federal health practice is committed to leading the way for U.S. government and public services (GPS) by leveraging AI-enabled, data-driven technology and scientific expertise. This will ultimately strengthen their ability to help government leaders protect the nation and ensure the health and safety of its citizens.
With this acquisition, Deloitte aims to provide a comprehensive range of biosafety services that can help organizations prepare for emergencies related to infectious diseases or other biological hazards.
The integration of Gryphon’s team with expertise in scientific communications will also play a crucial role in helping clients understand complex issues related to biosafety better.
Furthermore, this move highlights Deloitte’s commitment to using emerging technologies such as AI-enabled models to improve public health outcomes.
In conclusion, this acquisition by Deloitte is an important step towards providing a more comprehensive set of biosafety services that can help organizations prepare for emergencies related to infectious diseases or other biological hazards while leveraging cutting-edge technologies like AI-enabled models to improve public health outcomes.
